Used in research and therapeutic development for HIV and cancer due to its ability to block the CCR5 receptor. This receptor is a co-receptor for HIV entry into T-cells, so the antibody shows potential in preventing viral infection. It has been investigated in clinical trials for HIV treatment, particularly in patients with high viral loads or resistance to standard therapies. Also being explored in oncology, especially for triple-negative breast cancer, where CCR5 is involved in tumor progression and metastasis. By inhibiting CCR5, the antibody may reduce cancer cell migration and improve immune response. Used as a reference standard in immunoassays and antibody development due to its well-characterized binding properties.